Homocysteine inhibition of endothelium-dependent nitric oxide-mediated dilation of porcine retinal arterioles via enhanced superoxide production

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 3, 2013, Pages 2288-2295

  Omae, Tsuneaki ^a   Nagaoka, Taiji ^a   Tanano, Ichiro ^a   Yoshida, Akitoshi ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; APOCYNIN; HOMOCYSTEINE; HYDROETHIDINE; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PIOGLITAZONE; PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; SUPEROXIDE; TEMPOL; XANTHINE OXIDASE;

ARTERIOLE; ARTICLE; CANNULATION; CONFOCAL MICROSCOPE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; OXIDATIVE STRESS; PRIORITY JOURNAL; RETINA BLOOD FLOW; VASODILATATION; VIDEO MICROSCOPY;

ANIMALS; ARTERIOLES; BRADYKININ; CALCIMYCIN; ENDOTHELIUM, CORNEAL; HOMOCYSTEINE; HYPOGLYCEMIC AGENTS; NADPH OXIDASE; NITRIC OXIDE; PPAR GAMMA; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RETINAL ARTERY; SUPEROXIDES; SWINE; THIAZOLIDINEDIONES; VASODILATION; XANTHINE OXIDASE;

EID: 84875674738     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-11082     Document Type: Article

References (62)

1. Castro R, Rivera I, Blom HJ, Jakobs C, Tavares de Almeida I. Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: an overview. J Inherit Metab Dis. 2006;29:3-20.
2. Sen U, Mishra PK, Tyagi N, Tyagi SC. Homocysteine to hydrogen sulfide or hypertension. Cell Biochem Biophys. 2010;57:49-58.
3. Ubbink JB, Vermaak WJ, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr. 1993;57:47-53.
4. Hoogeveen EK, Kostense PJ, Eysink PE, et al. Hyperhomocysteinemia is associated with the presence of retinopathy in type 2 diabetes mellitus: the Hoorn study. Arch Intern Med. 2000; 160:2984-2990.
5. Brown BA, Marx JL, Ward TP, et al. Homocysteine: a risk factor for retinal venous occlusive disease. Ophthalmology. 2002; 109:287-290.
6. Ganapathy PS, White RE, Ha Y, et al. The role of N-methyl-Daspartate receptor activation in homocysteine-induced death of retinal ganglion cells. Invest Ophthalmol Vis Sci. 2011;52: 5515-5524.
7. Bleich S, Junemann A, von Ahsen N, et al. Homocysteine and risk of open-angle glaucoma. J Neural Transm. 2002;109: 1499-1504.
8. Seddon JM, Gensler G, Klein ML, Milton RC. Evaluation of plasma homocysteine and risk of age-related macular degeneration. Am J Ophthalmol. 2006;141:201-203.
9. Tyagi N, Sedoris KC, Steed M, Ovechkin AV, Moshal KS, Tyagi SC. Mechanisms of homocysteine-induced oxidative stress. Am J Physiol Heart Circ Physiol. 2005;289:H2649-2656.
10. Bellamy MF, McDowell IF, Ramsey MW, et al. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation. 1998;98: 1848-1852.
11. Touyz RM, Schiffrin EL. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascul Pharmacol. 2006;45:19-28.
12. Kleinhenz JM, Kleinhenz DJ, You S, et al. Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production. Am J Physiol Heart Circ Physiol. 2009;297:H1647-1654.
13. Mishra PK, Tyagi N, Sen U, Joshua IG, Tyagi SC. Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol. Cardiovasc Diabetol. 2010;9:49.
14. Hunt MJ, Tyagi SC. Peroxisome proliferators compete and ameliorate Hcy-mediated endocardial endothelial cell activation. Am J Physiol Cell Physiol. 2002;283:C1073-1079.
15. Omae T, Nagaoka T, Tanano I, Yoshida A. Pioglitazone, a peroxisome proliferator-activated receptor-{gamma} agonist, induces dilation of isolated porcine retinal arterioles: role of nitric oxide and potassium channels. Invest Ophthalmol Vis Sci. 2011;52:6749-6756.
16. Shen LQ, Child A, Weber GM, Folkman J, Aiello LP. Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol. 2008;126:793-799.
17. Dobrian AD, Schriver SD, Khraibi AA, Prewitt RL. Pioglitazone prevents hypertension and reduces oxidative stress in dietinduced obesity. Hypertension. 2004;43:48-56.
18. Mehta JL, Hu B, Chen J, Li D. Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation. Arterioscler Thromb Vasc Biol. 2003;23:2203-2208.
19. Hein TW, Yuan Z, Rosa RH Jr, Kuo L. Requisite roles of A2A receptors, nitric oxide, and KATP channels in retinal arteriolar dilation in response to adenosine. Invest Ophthalmol Vis Sci. 2005;46:2113-2119.
20. Hein TW, Xu W, Kuo L. Dilation of retinal arterioles in response to lactate: role of nitric oxide, guanylyl cyclase, and ATP-sensitive potassium channels. Invest Ophthalmol Vis Sci. 2006;47:693-699.
21. Nagaoka T, Hein TW, Yoshida A, Kuo L. Simvastatin elicits dilation of isolated porcine retinal arterioles: role of nitric oxide and mevalonate-rho kinase pathways. Invest Ophthalmol Vis Sci. 2007;48:825-832.
22. Kuo L, Davis MJ, Chilian WM. Endothelium-dependent, flowinduced dilation of isolated coronary arterioles. Am J Physiol. 1990;259:H1063-1070.
23. Jeppesen P, Aalkjaer C, Bek T. Bradykinin relaxation in small porcine retinal arterioles. Invest Ophthalmol Vis Sci. 2002;43: 1891-1896.
24. Lang D, Kredan MB, Moat SJ, et al. Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: role for superoxide anions. Arterioscler Thromb Vasc Biol. 2000;20:422-427.
25. Zhang C, Hein TW, Wang W, Kuo L. Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function. Circ Res. 2003;92:322-329.
26. Li L, Fink GD, Watts SW, et al. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in lowrenin hypertension. Circulation. 2003;107:1053-1058.
27. Cirillo PF, Pargellis C, Regan J. The non-diaryl heterocycle classes of p38 MAP kinase inhibitors. Curr Top Med Chem. 2002;2:1021-1035.
28. Bennett BL, Sasaki DT, Murray BW, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A. 2001;98:13681-13686.
29. Waugh J, Keating GM, Plosker GL, Easthope S, Robinson DM. Pioglitazone: a review of its use in type 2 diabetes mellitus. Drugs. 2006;66:85-109.
30. Seargent JM, Yates EA, Gill JH. GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation. Br J Pharmacol. 2004;143:933-937.
31. Emsley AM, Jeremy JY, Gomes GN, Angelini GD, Plane F. Investigation of the inhibitory effects of homocysteine and copper on nitric oxide-mediated relaxation of rat isolated aorta. Br J Pharmacol. 1999;126:1034-1040.
32. Tasatargil A, Dalaklioglu S, Sadan G. Poly(ADP-ribose) polymerase inhibition prevents homocysteine-induced endothelial dysfunction in the isolated rat aorta. Pharmacology. 2004;72: 99-105.
33. Fu YF, Xiong Y, Fu SH. Captopril restores endotheliumdependent relaxation of rat aortic rings after exposure to homocysteine. J Cardiovasc Pharmacol. 2003;42:566-572.
34. Jin L, Caldwell RB, Li-Masters T, Caldwell RW. Homocysteine induces endothelial dysfunction via inhibition of arginine transport. J Physiol Pharmacol. 2007;58:191-206.
35. Tasatargil A, Sadan G, Karasu E. Homocysteine-induced changes in vascular reactivity of guinea-pig pulmonary arteries: role of the oxidative stress and poly(ADP-ribose) polymerase activation. Pulm Pharmacol Ther. 2007;20:265-272.
36. Huang A, Koller A. Both nitric oxide and prostaglandinmediated responses are impaired in skeletal muscle arterioles of hypertensive rats. J Hypertens. 1996;14:887-895.
37. Nagaoka T, Kuo L, Ren Y, Yoshida A, Hein TW. C-reactive protein inhibits endothelium-dependent nitric oxide-mediated dilation of retinal arterioles via enhanced superoxide production. Invest Ophthalmol Vis Sci. 2008;49:2053-2060.
38. Zhang X, Li H, Jin H, Ebin Z, Brodsky S, Goligorsky MS. Effects of homocysteine on endothelial nitric oxide production. Am J Physiol Renal Physiol. 2000;279:F671-678.
39. Upchurch GR Jr, Welch GN, Fabian AJ, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem. 1997;272:17012-17017.
40. Chow K, Cheung F, Lao TT. Effect of homocysteine on the production of nitric oxide in endothelial cells. Clin Exp Pharmacol Physiol. 1999;26:817-818.
41. Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation. 2001;104:2569-2575.
42. Cheng Z, Yang X, Wang H. Hyperhomocysteinemia and endothelial dysfunction. Curr Hypertens Rev. 2009;5:158-165.
43. Au-Yeung KK, Woo CW, Sung FL, Yip JC, Siow YL. Hyperhomocysteinemia activates nuclear factor-kappaB in endothelial cells via oxidative stress. Circ Res. 2004;94:28-36.
44. Lee SJ, Kim KM, Namkoong S, et al. Nitric oxide inhibition of homocysteine-induced human endothelial cell apoptosis by down-regulation of p53-dependent Noxa expression through the formation of S-nitrosohomocysteine. J Biol Chem. 2005; 280:5781-5788.
45. Weiss N. Mechanisms of increased vascular oxidant stress in hyperhomocysteinemia and its impact on endothelial function. Curr Drug Metab. 2005;6:27-36.
46. Edirimanne VE, Woo CW, Siow YL, Pierce GN, Xie JY. Homocysteine stimulates NADPH oxidase-mediated superoxide production leading to endothelial dysfunction in rats. Can J Physiol Pharmacol. 2007;85:1236-1247.
47. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest. 1986;77:1370-1376.
48. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov. 2003;2:717-726.
49. Manning AM, Davis RJ. Targeting JNK for therapeutic benefit: from junk to gold? Nat Rev Drug Discov. 2003;2:554-565.
50. Bao XM, Wu CF, Lu GP. Atorvastatin attenuates homocysteineinduced apoptosis in human umbilical vein endothelial cells via inhibiting NADPH oxidase-related oxidative stress-triggered p38MAPK signaling. Acta Pharmacol Sin. 2009;30:1392-1398.
51. Dong F, Zhang X, Li SY, et al. Possible involvement of NADPH oxidase and JNK in homocysteine-induced oxidative stress and apoptosis in human umbilical vein endothelial cells. Cardiovasc Toxicol. 2005;5:9-20.
52. Parinandi NL, Kleinberg MA, Usatyuk PV, et al. Hyperoxiainduced NAD(P)H oxidase activation and regulation by MAP kinases in human lung endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2003;284:L26-38.
53. Naka KK, Papathanassiou K, Bechlioulis A, et al. Effects of pioglitazone and metformin on vascular endothelial function in patients with type 2 diabetes treated with sulfonylureas. Diab Vasc Dis Res. 2012;9:52-58.
54. Matsumoto T, Noguchi E, Kobayashi T, Kamata K. Mechanisms underlying the chronic pioglitazone treatment-induced improvement in the impaired endothelium-dependent relaxation seen in aortas from diabetic rats. Free Radic Biol Med. 2007; 42:993-1007.
55. Papaharalambus CA, Griendling KK. Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc Med. 2007;17:48-54.
56. Mercurio F, Manning AM. NF-kappaB as a primary regulator of the stress response. Oncogene. 1999;18:6163-6171.
57. Liu J, Xia Q, Zhang Q, et al. Peroxisome proliferator-activated receptor-gamma ligands 15-deoxy-delta(12,14)-prostaglandin J2 and pioglitazone inhibit hydroxyl peroxide-induced TNFalpha and lipopolysaccharide-induced CXC chemokine expression in neonatal rat cardiac myocytes. Shock. 2009;32: 317-324.
58. Drummond IA, Lee AS, Resendez E Jr, Steinhardt RA. Depletion of intracellular calcium stores by calcium ionophore A23187 induces the genes for glucose-regulated proteins in hamster fibroblasts. J Biol Chem. 1987;262:12801-12805.
59. Hill MA, Zou H, Potocnik SJ, Meininger GA, Davis MJ. Invited review: arteriolar smooth muscle mechanotransduction: Ca(2{thorn}) signaling pathways underlying myogenic reactivity. J Appl Physiol. 2001;91:973-983.
60. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042-1050.
61. Jacques PF, Rosenberg IH, Rogers G, et al. Serum total homocysteine concentrations in adolescent and adult Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr. 1999;69:482-489.
62. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149-1155.